scisparc secures fda green light to us launch of its pivotal phase iib clinical trial for breakthrough tourette syndrome treatment
FDA confirms that SciSparc’s study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE...